Please login to the form below
companion diagnostic
This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.
Merck gets first approval for MET inhibitor tepotinib in Japan
The approval comes on the back of a phase 2 study – called VISION – which enrolled patients with METex14-positive NSCLC based on a just-approved companion diagnostic developed by genome analysis
Latest news
-
Roche and Illumina partner on genomics for cancer diagnostics
Roche will collaborate with Illumina to complement its comprehensive pan-cancer blood assay TruSight Oncology 500 (TSO 500) with new companion diagnostic (CDx) claims. ... Building on the momentum of other recently established diagnostic and
-
Lynparza cleared for first-line ovarian cancer use in China
Around 22% of ovarian cancer patients carry a BRCA mutation (15% germline and 7% somatic), which must be identified via a companion diagnostic death.
-
GSK gets FDA okay for wider use of PARP drug Zejula
Zejula can be used in women who have been treated with three or more prior chemotherapy regimens and whose tumours are HRD-positive, identified using a just-approved companion diagnostic from ... In patients without BRCA mutations, but with a genomic
-
Roche undercuts price of Bayer cancer drug after winning FDA approval
Roche is working with Foundation Medicine to prepare a filing for FDA approval of the companion diagnostic, but for now no dedicated test is available. ... Vitrakvi also came to market without a companion diagnostic. Rozlytrek and Vitrakvi are part of a
-
Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund
Around 22% of ovarian cancer patients carry a BRCA mutation, which must be identified via a companion diagnostic test.
More from news
Approximately 1 fully matching, plus 61 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of precision medicine in oncology
a companion diagnostic. ... We are following a similar approach in lung cancer through an ongoing partnership to pursue a molecular diagnostic strategy for our early-stage investigational EGFR-MET bispecific antibody, which is being
-
Encouraging signs in biomarker R&D
The response has been a surge of interest in developing novel companion biomarkers, and biomarkers that allow personalisation of therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic
-
Drug launches to watch in 2019
At the moment there is no companion diagnostic for NTRK fusions so patients need to be identified through genomic profiling techniques such as immunohistochemistry or genetic sequencing approaches, which tend to
-
Harnessing complexity
This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a
-
Diagnostics are rising up the pharma value chain
Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
Mastering the precision medicine opportunity
Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new FoundationOne CDx, the first and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Sinopharm’s COVID-19 vaccine scores approval in China
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- AZ sells stake in Moderna for around $1.2bn
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
- CRM Design and Optimization for Life Science Organizations
- EMA begins rolling review process for Sputnik V COVID-19 vaccine
- MHRA to fast-track vaccines modified for new COVID-19 variants
- Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
